SEC Filing Summary

On June 4-5, 2026, Neil Kumar, CEO of BridgeBio Pharma, Inc. (BBIO), executed a series of stock sales totaling over 60,000 shares. These transactions were conducted under a Rule 10b5-1 sales plan. The sales, which occurred on June 4th and 5th, involved common stock sold at prices ranging from $65.145 to $69.51 per share. The sales were executed through various trusts, including the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, with Kumar acting as co-trustee for these entities. Following these transactions, the reporting person’s direct ownership of common stock decreased. The filing indicates that these transactions were not subject to Section 16 of the Securities Exchange Act of 1934. Specific details regarding the number of shares sold at each price within the reported ranges are available upon request.